Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-27T23:48:40.588Z Has data issue: false hasContentIssue false
  • English
  • Français

Scintigraphic evaluation of glomus tumours

Published online by Cambridge University Press:  29 June 2007

T. A. Rockall ,
J. C. Watkinson ,
S. E. M. Clark  and
E. E. Douek
T. A. Rockall*
Affiliation:
Departments of Otolaryngology, Guy's Hospital, London.
J. C. Watkinson
Affiliation:
Departments of Otolaryngology, Guy's Hospital, London. Departments of Nuclear Medicine, Guy's Hospital, London.
S. E. M. Clark
Affiliation:
Departments of Nuclear Medicine, Guy's Hospital, London.
E. E. Douek
Affiliation:
Departments of Otolaryngology, Guy's Hospital, London.
*
Dr T. A. Rockall, Department of Otolaryngology, Guys Hospital, St Thomas' Street, London SE1 9RT.
Get access Rights & Permissions [Opens in a new window]

Abstract

The current investigations of choice for a suspected glomus tumour are either direct or indirect angiography to include digital subtraction followed by computerized tomography (CT) or magnetic resonance imaging (MRI) or, if available, CT and MRI with gadolinium alone. Although these modalities confirm the diagnosis and give anatomical information to facilitate accurate staging, they do not provide functional data. The use of radionuclide scintigraphy can add an extra physiological dimension to glomus tumour imaging.

Iodine-131/123 metaiodobenzylguanidine (MIBG) is a tumour imaging agent which has been used to diagnose head and neck neuroendocrine tumours to include paragangliomata and medullary carcinoma of the thyroid (MCT). However, it is expensive and the new head and neck tumour imaging agent technetium-99 m (Tc99m) (v) dimercaptosuccinic acid (DMSA) has superceded it as the imaging agent of choice to evaluate MCT. We report a patient with a glomus jugulare tumour which was evaluated with I131/I123-MIBG and Tc99m (v) DMSA. The tumour was functional and is the first reported case exhibiting positive accumulation of both I131-MIBG and Tc99m (v) DMSA. The patient was subsequently treated with a therapeutic dose of I131-MIBG. The significance of these results is discussed.

Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 104 , Issue 1 , January 1990 , pp. 33 - 36
Copyright
Copyright © JLO (1984) Limited 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alford, B. R. and Guilford, F. R. (1962). A comprehensive study of tumours of the glomus jugulare. Laryngoscope, 72: 765–787.CrossRefGoogle ScholarPubMed
Azzarelli, B., Felten, S., Miyamoto, R., Muller, J. and Purvin, V. (1988). Dopamine in paragangliomas of the glomus jugulare. Laryngoscope, 98: 573–578.CrossRefGoogle ScholarPubMed
Baulieu, J. L., Guilloteau, D., Baulieu, D., Le Floch, O., Chambou, C., Pourcelot, L. and Besnard, J. C. (1988). Therapeutic effectiveness of iodine-131 MIBG. Metastases of anon-secreting paraganglioma. Journal of Nuclear Medicine, 29: 2008–2013.Google ScholarPubMed
Clarke, S. E. M., Lazarus, C. R., Watkinson, J., Edwards, S. and Maisey, M. N. (1987). 99Tcm (v) dimercaptosuccinic acid. Experience in imaging. (Abstract). Nuclear Medicine Communications, 8: 265.Google Scholar
Fischer, M., Kamanabroo, D., Sanderkamp, H. and Proske, T. (1984). Scintigraphic imaging of carcinoid tumours with 131I-MIBG (letter). Lancet, 2: 165.CrossRefGoogle Scholar
Guild, S. R. (1941). A hitherto unrecognized structure, the glomus jugularis. Anatomical records, Supplement 2, 79: 28.Google Scholar
Jackson, C. G., Glasscock, M. E. and Harris, P. F. (1982). Glomus tumours: diagnosis, classification and management of large lesions. Archives of Otolaryngology, 108: 401–406.CrossRefGoogle ScholarPubMed
Khafagi, F., Egerton-Vernon, J., van Doom, T., Foster, W., McPhee, I. B. and Allison, R. W. G. (1987). Localization and treatment of familial malignant non-functional paraganglioma with iodine-131 MIBG: Report of two cases. Journal of Nuclear Medicine, 28: 528–531.Google Scholar
Munkner, T. (1985). 131I-metaiodobenzylguanidine scintigraphy of neuroblastomas. Seminars in Nuclear Medicine. 15: 154–160.CrossRefGoogle Scholar
Ohta, H., Yamamoto, K., Endo, K., Mori, T., Hamanaka, D., Shimazu, A., Ikekubo, K., Makimoto, K., Iida, Y. and Konishi, J. (1984). Anew tumour imaging agent for medullary carcinoma of the thyroid. Journal of Nuclear Medicine. 25: 323–325.Google Scholar
Ohta, H., Endo, K., Fujita, T, Konishi, J., Torizuka, K., Horiuchi, K. and Yokoyama, A. (1988). Clinical evaluation of tumour imaging using 99Tcm (v) dimercaptosuccinic acid, a new tumour imaging agent. Nuclear Medicine Communications, 9: 105–116.Google Scholar
Rossenwasser, H. (1945). Carotid body tumour of the middle ear and mastoid. Archives of Otolaryngology, 41: 64–67.CrossRefGoogle Scholar
Sampson, C. B. (1987). Preparation of 99Tcm (v) DMSA. Nuclear Medicine Communications, 8(3): 184–185.Google Scholar
Shaheen, O. H. (1983). The management of tumours of the middle ear. Journal of Laryngology and Otology, 97: 313–317.CrossRefGoogle ScholarPubMed
Sisson, J. C., Frager, M. S., Valk, T. W., Gross, M. D., Swanson, D. P., Weiland, D. M., Tobes, M. C., Beierwaltes, W. H. and Thompson, N. W. (1981). Scintigraphic localization of phaeochromocytoma. New England Journal of Medicine 2, 305(1): 12–17.CrossRefGoogle Scholar
Sone, T., Fukunaga, M., Otsuka, N., Morita, R., Murunaku, A., Yanagimoto, S., Tomomitsu, T., Nakayama, H. and Harada, T. (1985). Metastatic medullary thyroid cancer: Localization with iodine-131-metaiodobenzylguanidine. Journal of Nuclear Medicine, 26: 604–608.Google ScholarPubMed
Spector, G. J., Ciralsky, R., Maisel, R. H., Ogura, J. H. (1974). Multiple glomus tumours in the head and neck. Laryngoscope, 85: 1066–1075.CrossRefGoogle Scholar
Taylor, D. M., Alford, B. R. and Greenberg, S. D. (1965). Metastases of glomus jugulare tumours. Archives of Otolaryngology, 82: 5–13.CrossRefGoogle Scholar
Veldman, J. E., Mulder, P. H. M., Ruijs, H. J., de Haas, G., Van Waes, P. F. G. M. and Hoekstra, A. (1980). Early detection of asymptomatic hereditary chemodectoma with radionuclide scintigraphy. Archives of Otolaryngology, 106: 547–552.CrossRefGoogle Scholar
Watkinson, J. C., Clarke, S. E. M. and Shaheen, O. H. (1987). An evaluation of the uptake of technetium-99m (v) dimercaptosuccinic acid in patients with squamous carcinoma of the head and neck. Clinical Otolaryngology, 12: 405–411.CrossRefGoogle ScholarPubMed
Watkinson, J. C., Lazarus, C. R., Mistry, R., Shaheen, O. H., Maisey, M. N. and Clarke, S. E. M. (1989 a). Technetium-99m (v) dimercaptosuccinic acid uptake in patients with head and neck squamous carcinoma. Journal of Nuclear Medicine, 30: 174–180.Google ScholarPubMed
Watkinson, J. C., Allen, S., Bharji, A., Lazarus, C., Maisey, M. N. and Clarke, S. E. M. (1989 b). A study of the pharmacokinetics, biodistribution and dosimetry of 99Tcm (v)-dimercaptosuccinic acid (Abstract). Nuclear Medicine Communications, 10: 238–239.Google Scholar